The incidence and impact of thrombocytopenia in myelodysplastic syndromes (Q33374593)

26 July 2017

1 reference

title

The incidence and impact of thrombocytopenia in myelodysplastic syndromes (English)

1 reference

26 July 2017

1 reference

1

Hagop Kantarjian

1 reference

26 July 2017

2

Francis Giles

1 reference

26 July 2017

6

Sherry Pierce

1 reference

26 July 2017

Alan List

3

1 reference

26 July 2017

Roger Lyons

4

1 reference

26 July 2017

Mikkael A Sekeres

5

1 reference

26 July 2017

Robert Deuson

7

1 reference

26 July 2017

Joseph Leveque

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

26 July 2017

1 reference

26 July 2017

volume

109

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1705-1714

1 reference

Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Increasing incidence of myelodysplastic syndromes: real or fictitious?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Prevalence of the myelodysplastic syndromes in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Incidence of myelodysplastic syndromes in a Swedish population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Establishing the incidence of myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Risk factors for myelodysplastic syndromes: a case-control study in Greece

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22602

1 reference

7 January 2021

Platelet function in preleukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Therapeutic efficacy of danazol in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all- trans -retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Vitamin D treatment in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Ocular complications in myelodysplastic syndromes as preleukemic disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Phase II study of roquinimex in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

13-cis retinoic acid treatment for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Danazol treatment of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Blood collection and transfusion in the United States in 1999.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Current issues with platelet transfusion in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Transfusion-transmitted bacterial infection in the United States, 1998 through 2000

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Platelet transfusions: utilization and associated costs in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Human platelets loaded with trehalose survive freeze-drying

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Pilot study of low-dose interleukin-11 in patients with bone marrow failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Guidelines for the use of platelet transfusions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22602

7 January 2021

Identifiers

DOI

10.1002/CNCR.22602

1 reference

release_ep3p3tyyqngrjlq7g5ggdx2zla

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ep3p3tyyqngrjlq7g5ggdx2zla

24 November 2022

mapped directly with Wikidata item

1 reference